首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   866711篇
  免费   72460篇
  国内免费   2485篇
耳鼻咽喉   12977篇
儿科学   24725篇
妇产科学   25249篇
基础医学   124693篇
口腔科学   25552篇
临床医学   76272篇
内科学   164565篇
皮肤病学   17066篇
神经病学   70138篇
特种医学   35548篇
外国民族医学   180篇
外科学   136775篇
综合类   26041篇
现状与发展   2篇
一般理论   264篇
预防医学   66940篇
眼科学   20777篇
药学   65632篇
  8篇
中国医学   2115篇
肿瘤学   46137篇
  2018年   7738篇
  2015年   8282篇
  2014年   11784篇
  2013年   17411篇
  2012年   23553篇
  2011年   24702篇
  2010年   14400篇
  2009年   13515篇
  2008年   23106篇
  2007年   25169篇
  2006年   25064篇
  2005年   24676篇
  2004年   24039篇
  2003年   23121篇
  2002年   22181篇
  2001年   35961篇
  2000年   36600篇
  1999年   30934篇
  1998年   8824篇
  1997年   8072篇
  1996年   7972篇
  1995年   8071篇
  1994年   7781篇
  1992年   26697篇
  1991年   26144篇
  1990年   25662篇
  1989年   24716篇
  1988年   23235篇
  1987年   22898篇
  1986年   21755篇
  1985年   21107篇
  1984年   16373篇
  1983年   13968篇
  1982年   8829篇
  1981年   8170篇
  1980年   7629篇
  1979年   16695篇
  1978年   12078篇
  1977年   10144篇
  1976年   9298篇
  1975年   10111篇
  1974年   12620篇
  1973年   12122篇
  1972年   11524篇
  1971年   10673篇
  1970年   10195篇
  1969年   9897篇
  1968年   8892篇
  1967年   8213篇
  1966年   7640篇
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
3.
Cognitive Therapy and Research - Despite interest in psychological inflexibility as a marker of suicide risk, no measure of psychological inflexibility specific to SI exists. The present study...  相似文献   
4.
5.
Gestational trophoblastic neoplasia (GTN) patients are treated according to the eight-variable International Federation of Gynaecology and Obstetrics (FIGO) scoring system, that aims to predict first-line single-agent chemotherapy resistance. FIGO is imperfect with one-third of low-risk patients developing disease resistance to first-line single-agent chemotherapy. We aimed to generate simplified models that improve upon FIGO. Logistic regression (LR) and multilayer perceptron (MLP) modelling (n = 4191) generated six models (M1-6). M1, all eight FIGO variables (scored data); M2, all eight FIGO variables (scored and raw data); M3, nonimaging variables (scored data); M4, nonimaging variables (scored and raw data); M5, imaging variables (scored data); and M6, pretreatment hCG (raw data) + imaging variables (scored data). Performance was compared to FIGO using true and false positive rates, positive and negative predictive values, diagnostic odds ratio, receiver operating characteristic (ROC) curves, Bland-Altman calibration plots, decision curve analysis and contingency tables. M1-6 were calibrated and outperformed FIGO on true positive rate and positive predictive value. Using LR and MLP, M1, M2 and M4 generated small improvements to the ROC curve and decision curve analysis. M3, M5 and M6 matched FIGO or performed less well. Compared to FIGO, most (excluding LR M4 and MLP M5) had significant discordance in patient classification (McNemar's test P < .05); 55-112 undertreated, 46-206 overtreated. Statistical modelling yielded only small gains over FIGO performance, arising through recategorisation of treatment-resistant patients, with a significant proportion of under/overtreatment as the available data have been used a priori to allocate primary chemotherapy. Streamlining FIGO should now be the focus.  相似文献   
6.
7.
The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular Screening and Therapeutic (MoST) Program are similar nonrandomized, multidrug, pan-cancer trial platforms that aim to identify signals of clinical activity of molecularly matched targeted therapies or immunotherapies outside their approved indications. Here, we report results for advanced or metastatic cancer patients with tumors harboring cyclin D-CDK4/6 pathway alterations treated with CDK4/6 inhibitors palbociclib or ribociclib. We included adult patients that had therapy-refractory solid malignancies with the following alterations: amplifications of CDK4, CDK6, CCND1, CCND2 or CCND3, or complete loss of CDKN2A or SMARCA4. Within MoST, all patients were treated with palbociclib, whereas in DRUP, palbociclib and ribociclib were assigned to different cohorts (defined by tumor type and alteration). The primary endpoint for this combined analysis was clinical benefit, defined as confirmed objective response or stable disease ≥16 weeks. We treated 139 patients with a broad variety of tumor types; 116 with palbociclib and 23 with ribociclib. In 112 evaluable patients, the objective response rate was 0% and clinical benefit rate at 16 weeks was 15%. Median progression-free survival was 4 months (95% CI: 3-5 months), and median overall survival 5 months (95% CI: 4-6 months). In conclusion, only limited clinical activity of palbociclib and ribociclib monotherapy in patients with pretreated cancers harboring cyclin D-CDK4/6 pathway alterations was observed. Our findings indicate that monotherapy use of palbociclib or ribociclib is not recommended and that merging data of two similar precision oncology trials is feasible.  相似文献   
8.
Die Anaesthesiologie - Der Mangel an automatischen externen Defibrillatoren (AED) und die fehlende Kenntnis von Ersthelfern im Umgang mit diesen Geräten haben in Deutschland zu einer...  相似文献   
9.
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号